BioPharma, Pharma Cancer Biotech Abdera Reveals $142M for Better Antibody-Based Radiation Drugs By Frank Vinluan
BioPharma, Pharma Novartis targeted radiation therapy gets FDA nod for advanced prostate cancer By Frank Vinluan
BioPharma, Pharma Curie Therapeutics unveils $75M to widen scope of radiopharmaceuticals for cancer By Frank Vinluan
BioPharma, Pharma Novartis is cashing out of Roche for $21B, 20 years after mega-merger that never happened By Frank Vinluan
BioPharma, Pharma Novartis radiopharmaceutical improves survival in key prostate cancer study By Frank Vinluan
BioPharma Novartis, Bristol Myers join $72M funding for startup’s cancer radiotherapy R&D By Frank Vinluan
BioPharma, Pharma Novartis spends $2.1B to snap up targeted radiotherapy drug for prostate cancer By Alaric DeArment
Devices & Diagnostics Which burgeoning medical device & pharma companies landed on Deloitte’s Fast 500 list? By
Health IT Allos Ventures will invest in the Midwest with new $40M fund for early-stage technologies By
